LONDON: The world’s most advanced malaria vaccine got the nod Friday (Saturday in Manila) from European regulators, despite mixed trial results, for eventual use in children in African countries plagued by the killer disease.

Dubbed Mosquirix or RTS,S, the drug received a “positive scientific opinion” from the European Medicines Agency (EMA) following decades of research and millions of dollars of investment.

Premium + Digital Edition

Ad-free access


P 80 per month
(billed annually at P 960)
  • Unlimited ad-free access to website articles
  • Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)

TRY FREE FOR 14 DAYS
See details
See details